{'fraction_non_alphanumeric': 0.011166253101736972, 'fraction_numerical': 0.0024813895781637717, 'mean_word_length': 5.560975609756097, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Combined contraceptives not effective for premenstrual depressive symptoms

study of women with schizophrenia. Use of antipsychotics that do not increase prolactin concentrations was not associated with an increased risk. Breast cancer is 25% more common among women with schizophrenia than in the general population, and breast cancer may be underdiagnosed in this group because women with schizophrenia are substantially less likely to be screened. It has been suspected that antipsychotics that block dopamine receptors and increase prolactin levels increase the risk of breast cancer, but research findings have been inconsistent. A cohort study examined the risk of breast cancer associated with exposure to antipsychotics, controlling for a number of other factors that can affect breast cancer risk.